Additionally, miR-126 has been described to modulate PI3K/AKT/mTOR and VEGF signaling [19,27], which are pathways that have been previously shown to be dysregulated in SSc pathogenesis [28,29]. The gene discussed is AKT1; the disease is systemic sclerosis.